Yungjin Pharm. Co., Ltd.
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
8%
1 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
Role: lead
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
Role: lead
Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination
Role: lead
A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis
Role: lead
Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers
Role: lead
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
Role: lead
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
Role: lead
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
Role: lead
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
Role: lead
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
Role: lead
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers
Role: lead
A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis
Role: lead
All 12 trials loaded